Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Am J Geriatr Psychiatry. 2012 Sep;20(9):789-97. doi: 10.1097/JGP.0b013e31823033f3.
The purposes of this study were first, to evaluate the effectiveness of citalopram in treating behavioral disturbances in frontotemporal dementia (FTD) subjects and second, to determine whether an association exists between serotonergic function, as determined by a neuroendocrine challenge, and treatment response.
Single-dose citalopram (30 mg per os) challenge followed by a 6-week open-label study.
Outpatients referred to memory clinics.
Fifteen patients suffering from FTD with severe behavioral and psychological symptoms of dementia.
Following citalopram challenge, all patients were treated with citalopram titrated to a target dose of 40 mg once daily.
Behavioral disturbances, using the Neuropsychiatric Inventory (NPI) (primary outcome) and Frontal Behavioural Inventory (secondary outcome), were assessed. Change in prolactin concentration following citalopram challenge was used as an index of central serotonergic response.
Citalopram treatment was effective in treating behavioral symptoms, with significant decreases in NPI total score (F[2, 28] = 6.644, p = 0.004), disinhibition (F[2, 28] = 4.030, p = 0.029), irritability (F[2, 28] = 7.497, p = 0.003) and depression (F[2, 28] = 3.467, p = 0.045) scores over the 6 weeks. Significant improvement in Frontal Behavioural Inventory scores suggested that citalopram was also effective in the treatment ofbehaviors specific to FTD. A lower change score in concentration of prolactin was significantly positively correlated with greater improvement in the total NPI score from baseline to endpoint (r = 0.687, p = 0.005). A blunted response to a citalopram challenge, implying a dysfunctional serotonergic system, predicted a more positive treatment outcome.
The results suggest that despite the endogenous serotonin deficiency of FTD, citalopram treatment may be effective in targeting the behavioral disturbances characteristic of FTD.
本研究的目的首先是评估西酞普兰治疗额颞叶痴呆(FTD)患者行为障碍的疗效,其次是确定神经内分泌挑战确定的 5-羟色胺能功能与治疗反应之间是否存在关联。
单次西酞普兰(30 mg 口服)挑战,随后进行 6 周的开放标签研究。
转诊至记忆诊所的门诊患者。
15 名患有 FTD 且伴有严重行为和心理症状的痴呆患者。
在西酞普兰挑战后,所有患者均接受西酞普兰治疗,剂量逐渐增加至目标剂量 40 mg 每日一次。
使用神经精神疾病问卷(NPI)(主要结局)和额叶行为量表(次要结局)评估行为障碍。西酞普兰挑战后催乳素浓度的变化被用作中枢 5-羟色胺反应的指标。
西酞普兰治疗可有效治疗行为症状,NPI 总分(F[2, 28] = 6.644,p = 0.004)、去抑制(F[2, 28] = 4.030,p = 0.029)、易激惹(F[2, 28] = 7.497,p = 0.003)和抑郁(F[2, 28] = 3.467,p = 0.045)评分在 6 周内均显著降低。额叶行为量表评分的显著改善表明,西酞普兰对 FTD 特定行为的治疗也有效。催乳素浓度变化评分较低与从基线到终点 NPI 总分的改善程度呈显著正相关(r = 0.687,p = 0.005)。西酞普兰挑战反应迟钝,暗示 5-羟色胺能系统功能障碍,预示着更积极的治疗效果。
结果表明,尽管 FTD 存在内源性 5-羟色胺缺乏,但西酞普兰治疗可能对靶向 FTD 特征性行为障碍有效。